Overview and Scope
Whole genome sequencing (WGS) and exome sequencing (ES) are comprehensive
genetic analysis techniques that involve determining the complete DNA sequence
of an organism's genome and sequencing the protein-coding regions of the
genome. These analyses are used to sequence a person's DNA for diagnosing
genetic diseases and identifying cancer mutations.
Sizing and Forecast
The whole genome and exome sequencing market size has grown exponentially in
recent years. It will grow from $1.61 billion in 2023 to $2.02 billion in 2024
at a compound annual growth rate (CAGR) of 25.5%. Thegrowth in the historic period can be
attributed to decreasing sequencing costs, rise in genetic disorders, clinical
applications, genomic data repositories, advancements in bioinformatics.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/whole-genome-and-exome-sequencing-global-market-report
Segmentation & Regional Insights
The whole genome and exome sequencing market covered in this report is
segmented –
1) By Product Type: Kits, Instruments
2) By Workflow: Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES)
3) By Applications: Diagnostics, Cancer, Monogenic Disorders, Diabetes, Drug
Discovery And Development, Personalized Medicine, Agriculture And Animal
Research, Other Applications
4) By End user: Research Center, Academic And Government Institutions,
Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End
Users
North America was the largest region in the whole genome and exome sequencing
market in 2023. Asia-Pacific is expected to be the fastest-growing region in
the forecast period. The regions covered in the whole genome and exome
sequencing market report are Asia-Pacific, Western Europe, Eastern Europe,
North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the
report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13957&type=smp
Major Driver Impacting Market Growth
The rising demand for personalized medicine is expected to propel the growth of
the whole genome and exome sequencing market in the future. Personalized
medicine is an approach to medical treatment that tailors healthcare decisions
and interventions to the individual characteristics of each patient,
considering factors such as genetics, environment, and lifestyle. Whole genome
and exome sequencing is used in personalized medicine by providing a
comprehensive analysis of an individual's genetic makeup, allowing for tailored
healthcare decisions and interventions based on their unique genetic,
environmental, and lifestyle factors. For instance, in October 2022, according
to the Personalized Medicine Coalition (PMC), a US-based organization that
promotes the understanding and adoption of personalized medicine, more than
75,000 genetic testing products and 300 personalized medicines are expected to
be on the market in 2022. Furthermore, the Food and Drug Administration's Center
for Drug Evaluation and Research (CDER) approved 37 new molecular entities
(NMEs) in 2022. Further, out of the 35 therapeutic NMEs, approximately 34%,
which amounts to 12 of them, are classified as personalized. Therefore, the
rising demand for personalized medicine is driving the growth of the whole
genome and exome sequencing market.
Key Industry Players
Major companies operating in the whole genome and exome sequencing market
report are Siemens AG, Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc.,
Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings
(Labcorp), Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc.,
Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V,
Neusoft Corporation, BGI Genomics, Mirion Technologies (Capintec) Inc.,
Novogene Co., Oxford Nanopore Technologies Inc., LANDAUER, Pacific Biosciences
of California Inc., Digirad Corporation, Berthold Technologies GmbH &
Co.KG, GENEWIZ Inc., Incom Inc., Lucerno Dynamics LLC, Absolute Imaging Inc.,
Mediso Ltd., Ashby Gorman Baker Ltd., DDD-Diagnostic AS, SurgicEye GmbH, CMR
Naviscan
The whole genome and exome sequencing market report table of contents includes:
1. Executive Summary
2. Whole Genome And Exome
Sequencing Market Characteristics
3. Whole Genome And Exome
Sequencing Market Trends And Strategies
4. Whole Genome And Exome
Sequencing Market - Macro Economic Scenario
5. Global Whole Genome And
Exome Sequencing Market Size and Growth
.
32. Global Whole Genome And
Exome Sequencing Market Competitive Benchmarking
33. Global Whole Genome And
Exome Sequencing Market Competitive Dashboard
34. Key Mergers And
Acquisitions In The Whole Genome And Exome Sequencing Market
35. Whole Genome And Exome
Sequencing Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
%20Edge%20Computing.jpg)
